Gainers
- Adicet Bio, Inc. (NASDAQ:ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma.
- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) rose 14.7% to $5.76 in pre-market trading after gaining over 7% on Thursday. Concert Pharmaceuticals recently announced topline results from its Phase 3 THRIVE-AA1 trial of CTP-543 in adult patients with moderate to severe alopecia areata (AA).
- Red Robin Gourmet Burgers, Inc. (NASDAQ:RRGB) rose 14.5% to $9.86 in pre-market trading after the company reported better-than-expected Q1 results.
- Solo Brands, Inc. (NYSE:DTC) shares rose 14.5% to $5.22 in pre-market trading. Solo Brands recently reported worse-than-expected Q1 sales results.
- Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares rose 14% to $1.22 in pre-market trading. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) shares rose 13.1% to $14.94 in pre-market trading. PMV Pharmaceuticals announced initial PC14586 Phase 1 clinical data to be presented at the 2022 American Society of Clinical Oncology Annual Meeting June 7.
- Dell Technologies Inc. (NYSE:DELL) rose 12.2% to $49.30 in pre-market trading after the company reported better-than-expected Q1 results.
- Redbox Entertainment Inc. (NASDAQ:RDBX) rose 11.3% to $8.40 in pre-market trading after gaining around 12% on Thursday. Redbox Entertainment recently acquired North American rights to WWII action-drama Come Out Fighting.
- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) rose 8.7% to $0.89 in pre-market trading. Oncternal Therapeutics presented updated interim data for zilovertamab in combination with ibrutinib at ASCO 2022.
- Ulta Beauty, Inc. (NASDAQ:ULTA) rose 8.5% to $410.05 in pre-market trading after the company reported better-than-expected Q1 results and raised FY22 net sales guidance.
- Catalyst Biosciences, Inc. (NASDAQ:CBIO) rose 7.2% to $1.19 in pre-market trading after dipping 22% on Thursday. Catalyst Biosciences recently announced it sold its complement portfolio for $60 million.
